A new, updated risk score can help predict possible contrast-associated acute kidney injury (CA-AKI) among patients undergoing percutaneous coronary intervention (PCI), Mount Sinai researchers report.
They said the simple and unique assessment tool can enhance management of patients at high risk of CA-AKI before, during, and after PCI, and improve their prognosis following the procedure.
The risk score, called “The Mehran-2 CA-AKI Risk Score,” was developed by Roxana Mehran, MD, Professor of Medicine (Cardiology), and Population Health Science and Policy, and Director of Interventional Cardiovascular Research and Clinical Trials at the Icahn School of Medicine at Mount Sinai, along with other Mount Sinai cardiologists. Their results were presented on Monday, November 15, at the American Heart Association Scientific Sessions 2021, with simultaneous publication in The Lancet.
Featured Faculty
Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, FSCAI
Director of Interventional Cardiovascular Research and Clinical Trials
Zena and Michael A. Wiener Cardiovascular Institute
Professor of Medicine (Cardiology)
Icahn School of Medicine at Mount Sinai
George Dangas, MD, PhD
Professor, Medicine (Cardiology, and Surgery)
Icahn School of Medicine at Mount Sinai
Director of Cardiovascular Innovation, The Zena and Michael A. Wiener Cardiovascular Institute
Mount Sinai Health System
